Skip to main content

Table 1 Baseline demographic and clinical characteristics of study subjects

From: The effect of temperature on the stability of PCSK-9 monoclonal antibody: an experimental study

Characteristics Patients (N = 9)
Age (yrs), mean ± SD 49.2 ± 18.4
Female gender, n (%) 6 (66.7%)
Diabetes mellitus, n (%) 6 (33.3%)
Hypertension, n (%) 4 (44.4%)
Cardiovascular disease, n (%) 1 (11.1%)
Statina, n (%) 8 (88.8%)
 Low-intensity statin 2
 Moderate-intensity statin 4
 High-intensity statin 2
Ezetimibe, n (%) 2 (22.2%)
Niacin and fenofibrate, n (%) 1 (11.1%)
Alcohol use, n (%) 1 (11.1%)
Laboratory profile, mean ± SD (range)
 Total cholesterol (mg/dL) 183.5 ± 53.5 (127.0–267.0)
 LDL-C (mg/dL) 108.1 ± 47.0 (61.8–185.6)
 Triglyceride (mg/dL) 96.3 ± 39.5 (47.0–150.0)
 HDL-C (mg/dL) 58.0 ± 16.9 (42.0–90.0)
 AST (U/L) 26.6 ± 13.0 (14.0–58.0)
 ALT (U/L) 22.4 ± 12.7 (10.0–47.0)
 BUN (mg/dL) 11.6 ± 2.9 (8.2–16.5)
 Creatinine (mg/dL) 0.8 ± 0.2 (0.53–1.14)
 Plasma PCSK9 level (ng/ml) 328.41 ± 70.6 (223.4–447.6)
  1. Abbreviations: SD standard deviation, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, AST aspartate transaminase, ALT alanine transaminase, BUN blood urea nitrogen, astatin: low intensity statin: simvastatin 10 mg/d, pravastatin 20 mg/d, moderate-intensity statin: simvastatin 20 mg/d, atorvastatin 20 mg/d, high-intensity statin: atorvastatin 40 and 80 mg/d
\